 Antiemetics
"Antiemetics" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used to prevent NAUSEA or VOMITING.
| Descriptor ID |
D000932
|
| MeSH Number(s) |
D27.505.696.663.050.030 D27.505.954.427.095 D27.505.954.483.200
|
| Concept/Terms |
Antiemetics- Antiemetics
- Antiemetic Drugs
- Drugs, Antiemetic
- Anti-emetics
- Anti emetics
- Antiemetic Agents
- Agents, Antiemetic
Antiemetic Effect- Antiemetic Effect
- Effect, Antiemetic
- Anti-Emetic Effects
- Anti Emetic Effects
- Effects, Anti-Emetic
- Antiemetic Effects
- Effects, Antiemetic
- Anti-Emetic Effect
- Anti Emetic Effect
- Effect, Anti-Emetic
|
Below are MeSH descriptors whose meaning is more general than "Antiemetics".
Below are MeSH descriptors whose meaning is more specific than "Antiemetics".
This graph shows the total number of publications written about "Antiemetics" by people in this website by year, and whether "Antiemetics" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 1 | 0 | 1 | | 1993 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 5 | 0 | 5 | | 1998 | 3 | 0 | 3 | | 1999 | 2 | 1 | 3 | | 2001 | 1 | 0 | 1 | | 2002 | 3 | 1 | 4 | | 2003 | 3 | 0 | 3 | | 2004 | 4 | 0 | 4 | | 2005 | 1 | 2 | 3 | | 2006 | 3 | 0 | 3 | | 2007 | 2 | 1 | 3 | | 2008 | 1 | 0 | 1 | | 2009 | 3 | 0 | 3 | | 2010 | 2 | 0 | 2 | | 2011 | 2 | 0 | 2 | | 2013 | 1 | 2 | 3 | | 2014 | 3 | 0 | 3 | | 2015 | 3 | 1 | 4 | | 2016 | 8 | 2 | 10 | | 2017 | 3 | 0 | 3 | | 2018 | 3 | 1 | 4 | | 2019 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Antiemetics" by people in Profiles.
-
Navari RM. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. Expert Opin Drug Saf. 2020 Feb; 19(2):205-210.
-
Navari RM. The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy. Expert Opin Drug Saf. 2019 Dec; 18(12):1127-1132.
-
Chow R, Aapro M, Navari RM, Gralla R, Chiu N, Chiu L, Chan S, Popovic M, Lam H, Lock M, DeAngelis C. Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis. Crit Rev Oncol Hematol. 2019 Oct; 142:164-186.
-
Basak S, Gicheru Y, Kapoor A, Mayer ML, Filizola M, Chakrapani S. Molecular mechanism of setron-mediated inhibition of full-length 5-HT3A receptor. Nat Commun. 2019 07 19; 10(1):3225.
-
Schwartzberg L, Roeland E, Andric Z, Kowalski D, Radic J, Voisin D, Rizzi G, Navari R, Gralla RJ, Karthaus M. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Ann Oncol. 2018 07 01; 29(7):1535-1540.
-
Chow R, Warr DG, Navari RM, Tsao M, Popovic M, Chiu L, Milakovic M, Lam H, DeAngelis C. Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis. Support Care Cancer. 2018 Aug; 26(8):2519-2549.
-
Schwartzberg LS, Navari RM. Safety of Polysorbate 80 in the Oncology Setting. Adv Ther. 2018 Jun; 35(6):754-767.
-
Navari RM. Managing Nausea and Vomiting in Patients With Cancer: What Works. Oncology (Williston Park). 2018 03 15; 32(3):121-5, 131, 136.
-
Ruddy KJ, Navari RM, Loprinzi CL. Thalidomide: Rebirth of a Gestational Antiemetic? J Clin Oncol. 2017 11 01; 35(31):3523-3524.
-
Rapoport BL, Aapro M, Chasen MR, Jordan K, Navari RM, Schnadig I, Schwartzberg L. Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations. Drug Des Devel Ther. 2017; 11:2621-2629.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|